2. Search Result
Search Result
Results for "

artery

" in MedChemExpress (MCE) Product Catalog:

172

Inhibitors & Agonists

2

Screening Libraries

6

Biochemical Assay Reagents

27

Peptides

1

Inhibitory Antibodies

21

Natural
Products

4

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122908
    Atuliflapon

    AZD5718

    		 FLAP Cardiovascular Disease
    Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5‑Lipoxygenase activating protein), with an IC50 of 2 nM. Atuliflapon is used in the study for coronary artery disease .
    Atuliflapon
  • HY-12424
    Zotarolimus
    4 Publications Verification

    ABT-578; A 179578

    		 Others Cardiovascular Disease Cancer
    Zotarolimus (ABT-578) is a derivative of rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis .
    Zotarolimus
  • HY-101393A
    CGP 12177 hydrochloride

    (±)-CGP 12177 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    CGP 12177 ((±)-CGP 12177) hydrochloride is a β Adrenergic Receptor Ligand. CGP 12177 hydrochloride is a high affinity antagonist of β1- and β2-AR. CGP 12177 hydrochloride is also shown to interact, with a lower affinity, with the β3-AR and to exhibit a partial agonist activity on rodent and human β3-AR. CGP 12177 hydrochloride exhibits partial agonist properties for α1-AR in rat pulmonary artery .
    CGP 12177 hydrochloride
  • HY-114672
    MBCQ

    		Phosphodiesterase (PDE) Cardiovascular Disease
    MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE .
    MBCQ
  • HY-P3433
    Sarafotoxin S6b

    		Endothelin Receptor Cardiovascular Disease
    Sarafotoxin S6b is a vasoconstrictor peptide, and a non-selective endothelin receptor agonist. Sarafotoxin S6b can induce contraction in isolated human coronary arteries , the Ki values of Coronary artery, Saphenous vein and Coronary artery are 0.27, 0.55 and 19.5 nM, respectively .
    Sarafotoxin S6b
  • HY-N1088
    Vindorosine

    Demethoxyvindoline

    		 Others Cardiovascular Disease
    Vindorosine is an alkaloid from Catharanthus trichophyllus Roots. Vindorosine relaxes renal arteries .
    Vindorosine
  • HY-114920
    Piprofurol

    		Calcium Channel Cardiovascular Disease
    Piprofurol is a calcium channel inhibitor. Piprofurol inhibits the calcium-induced contractions in isolated potassium depolarized preparations of rat aorta in a concentration-dependent manner and relaxes the K +-induced contraction of the dog coronary artery and the rabbit basilar artery. Piprofurol exerts a negative inotropic effect on guinea-pig papillary muscle, with the EC50 of 5 μM .
    Piprofurol
  • HY-19583
    Cicaprost

    ZK 96480

    		 Prostaglandin Receptor Cardiovascular Disease Cancer
    Cicaprost (ZK 96480) is a prostacyclin receptor (IP) agonist. Cicaprost causes a concentration-dependent relaxation of the artery with an EC50 of 5.8 nM 。
    Cicaprost
  • HY-118332
    19(R)-HETE

    		Others Cardiovascular Disease
    19(R)-HETE is a vasodilator in renal arteries, whereas 19(S)-HETE was relatively inactive .
    19(R)-HETE
  • HY-P3563
    [Lys4] Sarafotoxin S6c

    		Endothelin Receptor Cardiovascular Disease
    [Lys4] Sarafotoxin S6c, a sarafotoxin analogue, is a potent and partial agonist of endothelin receptor. [Lys4] Sarafotoxin S6c elicits contraction of pig coronary artery, with an EC50 of 1.5 nM .
    [Lys4] Sarafotoxin S6c
  • HY-15378
    Talibegron hydrochloride

    ZD2079 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease
    Talibegron hydrochloride (ZD2079 hydrochloride) is a potent β3-adrenoceptor agonist with a pD2 of 3.72 on phenylephrine-preconstricted rat mesenteric artery. Talibegron hydrochloride has potent vasorelaxant effect .
    Talibegron hydrochloride
  • HY-119770
    HDL376

    SDZ-HDL 376

    		 Others Cardiovascular Disease
    HDL376 is a scavenger receptor class B type I (SR-BI) inhibitor. HDL376 directly inhibits SR-BI-mediated lipid transport in cells and in liposomes reconstituted with purified SR-BI (IC50 = 0.22 μM). HDL376 can be used for the research of atherosclerotic coronary artery disease .
    HDL376
  • HY-122331
    Norbormide

    		Calcium Channel Cardiovascular Disease
    Norbormide shows vasoconstrictor activity by blocking calcium channel. The activity of Norbormide is species- and tissue-specific, endothelium independent, and is restricted to the peripheral arteries of rat. Norbormide is also a toxicant, and the oral LD50s in mouse, hamster, guinea pig and rabbit are 2250, 140, 620, and 1000 mg/kg .
    Norbormide
  • HY-P1112
    Sarafotoxin S6a

    		Endothelin Receptor Cardiovascular Disease Neurological Disease
    Sarafotoxin S6a, a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a elicits the pig coronary artery with an EC50 value of 7.5 nM .
    Sarafotoxin S6a
  • HY-12378
    BQ-123
    2 Publications Verification

    		 Endothelin Receptor Cardiovascular Disease
    BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM and a Ki of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .
    BQ-123
  • HY-P1112A
    Sarafotoxin S6a TFA

    		Endothelin Receptor Cardiovascular Disease Neurological Disease
    Sarafotoxin S6a TFA , a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a TFA elicits the pig coronary artery with an EC50 value of 7.5 nM .
    Sarafotoxin S6a TFA
  • HY-122237
    ATZ-1993

    		Endothelin Receptor Cardiovascular Disease
    ATZ-1993 is an orally active, nonpeptide endothelin receptor subtype Aand endothelin receptor subtype B antagonist with pKi values of 8.69, 7.20, respectively. ATZ-1993 has the potential for the research of intimal hyperplasia after balloon denudation of the carotid artery .
    ATZ-1993
  • HY-12378A
    BQ-123 TFA

    		Endothelin Receptor Cardiovascular Disease
    BQ-123 TFA is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM and a Ki of 25 nM. BQ-123 TFA inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension .
    BQ-123 TFA
  • HY-N0545
    Taurocholic acid sodium
    10+ Cited Publications

    Sodium taurocholate; N-Choloyltaurine sodium

    		 VEGFR Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid sodium (Sodium taurocholate) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid sodium has immunoregulation effect .
    Taurocholic acid sodium
  • HY-P2799H
    Creatine kinase-MB, Human heart

    CK-MB, Human heart

    		 Endogenous Metabolite Cardiovascular Disease
    Creatine kinase-MB (CK-MB), Human heart is a cardiac biomarker that can be used for early-phase risk detection of periprocedural myocardial infarction (PMI) after coronary artery bypass grafting (CABG) .
    Creatine kinase-MB, Human heart
  • HY-B1788
    Taurocholic acid
    10+ Cited Publications

    Taurocholic Acid

    		 Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
    Taurocholic acid
  • HY-123494
    BRD0418

    		Others Cardiovascular Disease Neurological Disease
    BRD0418 is a diversity-oriented synthesis (DOS) molecule that regulates the expression of tribbles pseudokinase 1. BRD0418 has the effect of causing hot lipoprotein metabolism from fat production to clearance. BRD0418 can be used in the study of coronary artery disease (CAD) .
    BRD0418
  • HY-B1815
    Xanthinol Nicotinate

    Xanthinol Niacinate

    		 Others Cardiovascular Disease
    Xanthinol Nicotinate (Xanthinol Niacinate), a vasodilator, can act directly on the smooth muscle of small arteries and capillaries. Xanthinol Nicotinate expands blood vessels, improves blood rheology and reduces peripheral vascular resistance .
    Xanthinol Nicotinate
  • HY-106586A
    Ioxaglate sodium

    P-286 sodium

    		 Biochemical Assay Reagents Cardiovascular Disease Cancer
    Ioxaglate sodium (P-286 sodium) is an ionic, dimeric diagnostic contrast agent whose activity is mainly reflected in its ability to provide sufficient X-ray absorption to enhance visualization of blood vessels and other structures during imaging. Ioxaglate sodium is used to study the anatomical structure and functional status of cardiac vessels, especially in the diagnosis of coronary artery disease .
    Ioxaglate sodium
  • HY-124304
    Pinokalant

    LOE-908

    		 TRP Channel SARS-CoV Neurological Disease
    Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity .
    Pinokalant
  • HY-139727
    S(-)-Bisoprolol

    		Adrenergic Receptor Cardiovascular Disease
    S(-)-Bisoprolol is a S(-)-enantiomer of Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
    S(-)-Bisoprolol
  • HY-139727A
    S(-)-Bisoprolol fumarate

    		Adrenergic Receptor Cardiovascular Disease
    S(-)-Bisoprolol fumarate is a S(-)-enantiomer of Bisoprolol fumarate. Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research .
    S(-)-Bisoprolol fumarate
  • HY-118284
    Vicagrel
    1 Publications Verification

    		 P2Y Receptor Cardiovascular Disease
    Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease .
    Vicagrel
  • HY-137227
    15(R)-PTA2

    15(R)-Pinanethromboxane A2

    		 Others Cardiovascular Disease
    15(R)-PTA2 (15(R)-Pinanethromboxane A2) is an antithrombotic agent that inhibits platelet aggregation. 15(R)-PTA2 inhibits stable prostaglandin endoperoxide analog-induced constriction of feline coronary arteries and stabilizes hepatic lysosomes. 15(R)-PTA2 also inhibits thromboxane synthase but has no effect on prostacyclin synthase .
    15(R)-PTA2
  • HY-B1788R
    Taurocholic acid (Standard)

    		Endogenous Metabolite Inflammation/Immunology
    Taurocholic acid (Standard) is the analytical standard of Taurocholic acid. This product is intended for research and analytical applications. Taurocholic acid (N-Choloyltaurine) has marked bioactive effects such as an inhibitory potential against hepatic artery ligation induced biliary damage by upregulation of VEGF-A expression. Taurocholic acid has immunoregulation effect .
    Taurocholic acid (Standard)
  • HY-B0813
    Treprostinil diethanolamine
    1 Publications Verification

    UT-15C

    		 Prostaglandin Receptor Endocrinology
    Treprostinil (UT-15C) diethanolamine is a potent EP2, DP1 and IP agonist with Ki values of 3.6, 4.4, 32.1, 212, 826, 2505 and 4680 nM for EP2, DP1, IP, EP1, EP4, EP3 and FP, respectively. Treprostinil (UT-15C) diethanolamine increases upregulation of cAMP toward maintaining homeostasis within the vasculature. Treprostinil (UT-15C) diethanolamine can result in vasodilatation of human pulmonary arteries .
    Treprostinil diethanolamine
  • HY-100206
    5α-Androstane-3β,5,6β-triol

    		AMPK Neurological Disease
    5α-Androstane-3β,5,6β-triol is a neuroprotectant. 5α-Androstane-3β,5,6β-triol can remarkably reverse intracellular acidification and alleviate neuronal injury through the inhibition of AMPK signaling. 5α-Androstane-3β,5,6β-triol remarkably reduced the infarct volume and attenuated neurologic impairment in acute ischemic stroke models of middle cerebral artery occlusion in vivo .
    5α-Androstane-3β,5,6β-triol
  • HY-121208
    Ketanserinol

    R 46742

    		 5-HT Receptor Drug Metabolite Neurological Disease
    Ketanserinol (R 46742) is a metabolite of Ketanserin (HY-10562). Ketanserinol is a competitive antagonist of the effects of 5-HT (HY-B1473A) in both arteries. The KB values are 6.5 for large coronary arteries and 6.4 for pulmonary arteries .
    Ketanserinol
  • HY-14654
    Aspirin
    15+ Cited Publications

    Acetylsalicylic Acid; ASA

    		 COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Acetylsalicylic Acid) is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin induces apoptosis. Aspirin inhibits the activation of NF-κB. Aspirin also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin
  • HY-14654C
    Aspirin calcium

    Acetylsalicylic acid calcium; ASA calcium

    		 COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin calcium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin calcium induces apoptosis. Aspirin calcium inhibits the activation of NF-κB. Aspirin calcium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin calcium
  • HY-106954
    Upidosin

    Rec 15/2739; Recordati 15/2739; SB 216469

    		 Adrenergic Receptor Inflammation/Immunology
    Upidosin (Rec 15/2739) is an α-1 adrenoceptor (α-1 AR) antagonist. Upidosin shows moderate selectivity for the α-1A AR subtype. Upidosin shows uroselectivity in urethra and prostate with a Kb value of 2-3 nM higher than in ear artery and aorta with a Kb value of 20-100 nM. Upidosin inhibits [3H]prazosin binding to cloned human α-1A adrenergic receptor. Upidosin can be used for the research of urethral obstruction .
    Upidosin
  • HY-14654A
    Aspirin lithium

    Acetylsalicylic Acid lithium; ASA lithium

    		 COX Virus Protease NF-κB Autophagy Apoptosis Mitophagy Caspase p38 MAPK Infection Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
    Aspirin (Acetylsalicylic Acid) lithium is an orally active, potent and irreversible inhibitor of cyclooxygenase COX-1 and COX-2, with IC50 values of 5 and 210 μg/mL, respectively. Aspirin lithium induces apoptosis. Aspirin lithium inhibits the activation of NF-κB. Aspirin lithium also inhibits platelet prostaglandin synthetase, and can prevent coronary artery and cerebrovascular thrombosis .
    Aspirin lithium
  • HY-D1501
    Fura PE-3 potassium

    		Fluorescent Dye Others
    Fura PE-3 potassium is a Ca 2+sensitive fluorophore. Fura PE-3 potassium loads in IPA (intrapulmonary arteries) and MA (mesenteric resistance arteries) for the research of vasoconstriction .
    Fura PE-3 potassium
  • HY-B0203
    Nebivolol

    R 065824

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Nebivolol (R 065824) is an orally active beta receptor blocker and has the high beta(1)-receptor affinity. Nebivolol has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol
  • HY-B0203A
    Nebivolol hydrochloride
    3 Publications Verification

    R 065824 hydrochloride

    		 Adrenergic Receptor Cardiovascular Disease Endocrinology
    Nebivolol (R 065824) hydrochloride is an orally active beta receptor blocker and has the high beta(1)-receptor affinity.Nebivolol hydrochloride has direct vasodilator properties and adrenergic blocking characteristics. Nebivolol hydrochloride can be used for the research of kinds of diseases such as hypertension, coronary artery disease, congestive heart failure and ischemic heart disease .
    Nebivolol hydrochloride
  • HY-126049
    (S)-Oxiracetam

    (S)-(-)-Oxiracetam; (S)-ISF2522

    		 Apoptosis Neurological Disease
    (S)-oxiracetam (S-ORC) is an inhibitor targeting apoptosis. S-ORC reduces brain infarct size and lessens neurological dysfunction in middle cerebral artery occlusion/reperfusion (MCAO/R) models. S-ORC prevents neuronal apoptosis via activating PI3K/Akt/GSK3β signaling pathway via α7 nAChR after ischemic stroke. S-ORC can prevent neuronal death after ischemic stroke .
    (S)-Oxiracetam
  • HY-117572
    MRS2567

    		Others Others
    MRS2567 is a P2Y receptor antagonist with the activity of inhibiting contraction of mouse mesenteric arteries. MRS2567 can inhibit the sustained contraction caused by UTP and UDP, and inhibit the Na?, K?, 2Cl? co-transport-dependent signaling pathway, thereby affecting the myogenic tone of mouse mesenteric arteries.
    MRS2567
  • HY-U00147
    Nicotinoyl cyclandelate

    RV 12128

    		 Others Cardiovascular Disease
    Nicotinoyl cyclandelate can be used to lower the perfusion pressure of cerebral blood vessels and the blood pressure of femoral artery.
    Nicotinoyl cyclandelate
  • HY-44809A
    Izilendustat hydrochloride

    		HIF/HIF Prolyl-Hydroxylase Inflammation/Immunology Cancer
    Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1) .
    Izilendustat hydrochloride
  • HY-133594
    Sandaracopimaric acid

    		Others Cardiovascular Disease Inflammation/Immunology
    Sandaracopimaric acid is a diterpenoid with anti-inflammatory effect. Sandaracopimaric acid reduces the contraction of phenylephrine-induced pulmonary arteries with an EC50 of 43.93 μM .
    Sandaracopimaric acid
  • HY-13056
    SMND-309

    		Drug Metabolite Neurological Disease
    SMND-309 is a metabolite of salvianolic acid B, and exhibits neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats .
    SMND-309
  • HY-111804
    3',4'-Dihydroxyflavonol

    DiOHF

    		 NO Synthase Cardiovascular Disease Metabolic Disease
    3',4'-Dihydroxyflavonol (DiOHF) is an effective antioxidant, which reduces superoxide and improves nitric oxide (NO) function in diabetic rat mesenteric arteries .
    3',4'-Dihydroxyflavonol
  • HY-108564
    L 655240

    		Prostaglandin Receptor Cardiovascular Disease
    L 655240 is thromboxane antagonist. L 655240 attenuates early ischemia- and reperfusion-induced arrhythmias in a canine model of coronary artery occlusion. L 655240 also involves in cancer and autoimmune disorders .
    L 655240
  • HY-I0400
    N-Acetylneuraminic acid
    3 Publications Verification

    NANA; Lactaminic acid

    		 Tyrosinase Ras Influenza Virus Endogenous Metabolite Cardiovascular Disease Inflammation/Immunology Cancer
    N-Acetylneuraminic acid (NANA; Lactaminic acid), a nonphenolic structure, is the predominant form of sialic from Collocalia esculenta. N-Acetylneuraminic acid plays a biological role in myocardial injury, melanoma and viral or bacterial infection. N-Acetylneuraminic acid inhibits melanogenesis by reducing tyrosinase activity and triggers myocardial injury in vitro and in vivo by activation of the Rho/Rho-associated signaling pathway through binding to RhoA and Cdc42. N-Acetylneuraminic acid may prevent high fat diet (HFD)-induced inflammation and oxidative stress, thereby prevents hyperlipidemia-associated inflammation and oxidative stress. N-Acetylneuraminic acid is promising for research in the field of melanoma, coronary artery, obesity-related diseases and hyperlipidemia .
    N-Acetylneuraminic acid
  • HY-100613
    MONNA

    		Chloride Channel Cardiovascular Disease
    MONNA is a potent transmembrane protein 16A (TMEM16A, Anoctamin-1) blocker with an IC50 of 80 nM. MONNA induces vasorelaxation of rodent resistance arteries in presence or absence of chloride ions .
    MONNA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: